目的 觀察芩香清解口服液聯合奧司他韋治療甲型流感的臨床療效。方法 選取2020年3月—2022年2月中國中醫(yī)科學院廣安門醫(yī)院收治的164例甲型流感患兒，按照隨機數字表法將所有患者分為對照組和治療組，每組各82例。對照組口服磷酸奧司他韋顆粒，每次用藥劑量根據患兒體質量而定，體質量＜15 kg，30 mg/次；體質量15～23 kg，45 mg/次；體質量23～40 kg，60 mg/次；體質量＞40 kg，75 mg/次；2次/d。治療組在對照組基礎上口服芩香清解口服液，每次用量根據患兒年齡段而定，1～3歲，5 mL/次；3～7歲，10 mL/次；7～14歲，15 mL/次；3次/d。兩組均連續(xù)治療5 d。觀察兩組臨床療效、退熱效果，咽痛、便秘的消失時間及病毒核酸轉陰率。比較治療前后兩組外周血中性粒細胞與淋巴細胞比值（NLR）和血清腫瘤壞死因子（TNF）-α、白細胞介素（IL）-8、C反應蛋白（CRP）水平。結果 治療后，治療組總有效率97.6%，顯著高于對照組的89.0%（P＜0.05）。治療后，治療組退熱起效時間和完全退熱時間均較對照組顯著縮短，即刻退熱率68.3%較對照組52.4%顯著提高（P＜0.05）。治療后，治療組咽痛、便秘的消失時間均顯著短于對照組，病毒核酸轉陰率92.7%顯著高于對照組的81.7%（P＜0.05）。與治療前相比，治療后患者兩組外周血NLR和血清TNF-α、IL-8、CRP水平均顯著下降（P＜0.05）；且治療后，治療組外周血NLR和血清TNF-α、IL-8、CRP水平均顯著低于對照組（P＜0.05）。結論 芩香清解口服液聯合奧司他韋治療甲型流感具有顯著的退熱效果，能有效減輕患兒相關癥狀、控制病毒感染，并可進一步緩解機體炎癥反應，且安全性好。

Objective To observe the clinical efficacy of Qinxiang Qingjie Oral Liquid combined with oseltamivir in treatment of influenza A in children. Methods A total of 164 children with influenza A treated in Guang’anmen Hospital of China Academy of Chinese Medical Sciences from March 2020 to February 2022 were selected. All patients were divided into control group and treatment group according to the random number table method, with 82 cases in each group. Patients in the control group were po administered with Oseltamivir Phosphate Granules, each dose was determined according to the weight of the child, body weight < 15 kg, 30 mg/time. The body weight was 15-23 kg, 45 mg/time. The body weight was 23-40 kg, 60 mg/ time. Body weight > 40 kg, 75 mg/ time, twice daily. Patients in the treatment group were po administered with Qinxiang Qingjie Oral Liquid on the basis of the control group, the dosage was determined according to the age of the child, 1 to 3 years old, 5 mL/time; 3 to 7 years old, 10 mL/time; 7 to 14 years old, 15 mL/time, three times daily. Both groups were treated for 5 d. The clinical efficacy, antipyretic effect, disappearance time of sore throat, constipation and negative rate of viral nucleic acid were observed in the two groups. The ratio of neutrophils to lymphocytes (NLR) in peripheral blood, the levels of tumor necrosis factor (TNF) -α, interleukin (IL) -8 and C-reactive protein (CRP) in serum were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 97.6%, which was significantly higher than 89.0% of the control group (P < 0.05). After treatment, the antipyretic onset time and complete antipyretic time of the treatment group were significantly shorter than those of the control group, and the immediate antipyretic rate was 68.3%, which was significantly higher than that of the control group 52.4% (P < 0.05). After treatment, the disappearance time of sore throat and constipation in the treatment group was significantly shorter than that in the control group, and the negative rate of viral nucleic acid was 92.7%, which was significantly higher than 81.7% in the control group (P < 0.05). Compared with before treatment, the levels of peripheral blood NLR and serum TNF-α, IL-8 and CRP in the two groups were significantly decreased after treatment (P < 0.05). After treatment, the levels of peripheral blood NLR and serum TNF-α, IL-8 and CRP in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Qinxiang Qingjie Oral Liquid combined with oseltamivir has a significant antipyretic effect in treatment of influenza A, can effectively relieve the symptoms of patients, control the virus infection, and further relieve the body’s inflammatory response with good safety.

R974;R985